John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) President John Volpone sold 24,576 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $109,117.44. Following the transaction, the president directly owned 265,305 shares in the company, valued at approximately $1,177,954.20. This represents a 8.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

X4 Pharmaceuticals Trading Down 1.6%

NASDAQ:XFOR opened at $4.22 on Friday. X4 Pharmaceuticals, Inc. has a 12 month low of $2.45 and a 12 month high of $4.83. The company has a current ratio of 11.30, a quick ratio of 9.98 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $418.40 million, a price-to-earnings ratio of -3.52 and a beta of 0.37. The firm has a fifty day simple moving average of $4.05 and a two-hundred day simple moving average of $3.96.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. The firm had revenue of $8.81 million for the quarter, compared to analyst estimates of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. Analysts expect that X4 Pharmaceuticals, Inc. will post -0.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Leerink Partners initiated coverage on X4 Pharmaceuticals in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price target on the stock. Weiss Ratings cut X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Finally, Wells Fargo & Company began coverage on X4 Pharmaceuticals in a research report on Friday, July 10th. They set an “overweight” rating and a $11.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, X4 Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.25.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new stake in shares of X4 Pharmaceuticals during the second quarter worth about $917,000. Pettinga Financial Advisors LLC bought a new position in X4 Pharmaceuticals in the 2nd quarter valued at about $47,000. Perceptive Advisors LLC boosted its stake in X4 Pharmaceuticals by 6.7% during the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock valued at $27,826,000 after purchasing an additional 423,196 shares during the last quarter. Bank of America Corp DE boosted its stake in X4 Pharmaceuticals by 321.3% during the 1st quarter. Bank of America Corp DE now owns 150,676 shares of the company’s stock valued at $622,000 after purchasing an additional 114,915 shares during the last quarter. Finally, SummitTX Capital L.P. bought a new stake in X4 Pharmaceuticals during the 1st quarter worth approximately $46,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.